New hope for kids with hepatitis b: interferon trial aims for functional cure
NCT ID NCT07231276
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a weekly injection of pegylated interferon alfa-2b for 48 weeks can help children and teens (ages 3–17) with chronic hepatitis B achieve a functional cure. The treatment group will be compared to an observation group receiving no drug or standard antivirals. The goal is to see if the drug can clear the virus and improve immune responses, potentially leading to better long-term outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pegylated interferon alfa-2b
What this could lead to
If successful, this could point toward a functional cure for chronic hepatitis B in children and teens, reducing their lifelong infection risk.
What could go wrong
This is a phase 4 study with only 113 participants, so results may not apply to everyone. Interferon can cause flu-like symptoms and other side effects, and a functional cure is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HBV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanfang Hospital
Guangzhou, Guangdong, 510515, China
Contact Phone: •••-•••-•••• Email: •••••@•••••